One less dose of HPV vaccine to prevent cancer
Menée par modélisation mathématique et à partir de données portant sur la population générale dans quatre pays à faible revenu ou à revenu intermédiaire (Inde, Nigéria, Ouganda, Viêtnam), cette étude analyse, chez les jeunes filles, l'efficacité d'une vaccination monodose contre le papillomavirus humain (HPV) par rapport à deux doses de vaccin
The landmark research by Élodie Bénard and colleagues in this issue of The Lancet Public Health supports one less dose of human papillomavirus (HPV) vaccine than is currently approved for children aged 9–14 years.1 Around 125 countries have introduced HPV vaccines for girls aged 9–14 years. Seven countries will introduce programmes in 2023.2 Building on the accumulating data that show the comparative efficacy and immunogenicity of one dose of HPV vaccine compared with two, Bénard and colleagues report compelling data supporting a one-dose vaccine strategy. The comprehensive modelling in this study assumes a minimum duration of protection for the single HPV dose of 20 years. The opportunity to move to one dose offers significant advantages in cost saving and administrative simplicity. With vaccination starting at 9 years of age, the antibody efficacy will prevent infections until women reach their local screening age, possibly longer.